View ValuationVimian Group 향후 성장Future 기준 점검 3/6Vimian Group (는) 각각 연간 28% 및 8.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 26.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 9.2% 로 예상됩니다.핵심 정보28.0%이익 성장률26.15%EPS 성장률Medical Equipment 이익 성장16.1%매출 성장률8.7%향후 자기자본이익률9.17%애널리스트 커버리지Low마지막 업데이트18 Feb 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 29Vimian Group AB (publ) to Report Fiscal Year 2026 Results on Feb 11, 2027Vimian Group AB (publ) announced that they will report fiscal year 2026 results on Feb 11, 2027공시 • Dec 24Vimian Group AB (publ) (OM:VIMIAN) entered into an agreement to acquire I-Vet S.R.L. from the Franzini family.Vimian Group AB (publ) (OM:VIMIAN) entered into an agreement to acquire I-Vet S.R.L. from the Franzini family on December 23, 2025. The acquisition is financed with available funds. Following the acquisition, I-Vet will be integrated into Vimian’s Diagnostics segment, and CEO Daniele Franzini will continue to lead I-Vet as part of Vimian. For the period ending December 31, 2024, I-Vet S.R.L. reported total revenue of €5.6 million and has 75 team members. The acquisition is expected to be completed on or around March 2, 2026. The acquisition is expected to have marginal impact on earnings per share in the 2026 financial year.공시 • Nov 24+ 1 more updateVimian Group AB (publ) Announces CEO ChangesVimian Group AB (publ) appointed Alireza Tajbakhsh as Chief Executive Officer, effective 24 November 2025. Alireza Tajbakhsh joined Vimian in 2021 and is currently Head of the Veterinary Services segment and interim Head of the MedTech segment in Vimian. Alireza Tajbakhsh (42) brings extensive international leadership experience from fast-growing entrepreneurial companies in the media and life science sectors. Since joining Vimian in 2021, he has successfully led the Veterinary Services segment and served as a member of the group management team. Since July 2025, he has also held the interim position as Head of Vimian’s MedTech segment, delivering strong early progress and results. Prior to joining Vimian, Alireza held senior management positions at Omnicom Media Group and Modern Times Group (MTG). Alireza holds an M.Sc. in Business and Administration from the Stockholm School of Economics. The board thank Carl-Johan Zetterberg Boudrie for capably serving as interim CEO in addition to his role as CFO over the past months. Carl-Johan Zetterberg will continue as a strong partner to Ali in his position as CFO. Alireza Tajbakhsh will, in addition to the role as Group CEO, continue to hold the interim operational responsibility for Vimian's MedTech segment, while the recruitment for a permanent Head of MedTech is ongoing.공시 • Oct 20Vimian Group AB (publ) to Report Fiscal Year 2025 Final Results on Mar 19, 2026Vimian Group AB (publ) announced that they will report fiscal year 2025 final results on Mar 19, 2026공시 • Sep 23Vimian Group AB (publ), Annual General Meeting, Apr 29, 2026Vimian Group AB (publ), Annual General Meeting, Apr 29, 2026.공시 • Sep 16+ 2 more updatesVimian Group AB (publ) to Report Q1, 2026 Results on Apr 29, 2026Vimian Group AB (publ) announced that they will report Q1, 2026 results on Apr 29, 2026공시 • Jul 18+ 1 more updateVimian Group AB Announces Executive Management Changes, Effective 17 July 2025Vimian Group AB announced that effective today, Alireza Tajbakhsh will, in addition to his current role as Head of Vimian’s Veterinary Services segment, assume interim operational responsibility for Vimian’s MedTech segment. He succeeds Guy Spörri, who has decided to leave the company at year-end. Furthermore, Bart Bremer, Chief People Officer, is appointed as a member of Vimian’s executive management team.공시 • Jun 13Vimian Group AB (publ) (OM:VIMIAN) signed an agreement to acquire AllAccem Inc.Vimian Group AB (publ) (OM:VIMIAN) signed an agreement to acquire AllAccem Inc. on June 13, 2025. AllAccem Inc. had revenues of around $9 million for the twelve months ending April 2025, and an EBITDA margin significantly above the Vimian Group average. AllAccem will become part of Vimian’s MedTech segment and Jeffery Whiteford, founder and CEO of AllAccem Inc., will continue to lead the integrated business. The acquisition is expected to have marginal impact on earnings per share in the current financial year. The acquisition of AllAccem Inc. is expected to be completed on or around 13 June and is financed with available funds.공시 • Apr 30Vimian Group AB (publ) Elects Pia Marions as Board MemberVimian Group AB (publ) at its Annual General Meeting held on 29 April 2025, Pia Marions was newly elected, as Board members for the time until the end of the next Annual General Meeting.공시 • Mar 14Vimian Group AB (publ) to Report Q4, 2025 Results on Feb 12, 2026Vimian Group AB (publ) announced that they will report Q4, 2025 results on Feb 12, 2026공시 • Dec 04+ 3 more updatesVimian Group AB (publ) to Report Q2, 2025 Results on Jul 18, 2025Vimian Group AB (publ) announced that they will report Q2, 2025 results on Jul 18, 2025공시 • Oct 12Vimian Group AB (publ), Annual General Meeting, Apr 29, 2025Vimian Group AB (publ), Annual General Meeting, Apr 29, 2025.공시 • May 23Vimian Group AB (publ) Elects Magnus Welander to Board as Chairman of the BoardVimian Group AB (publ) at its Annual General Meeting held on 22 May 2024 announced that Magnus Welander was newly elected, as Board members for the time until the end of the next Annual General Meeting. Magnus Welander was elected as chairman of the Board.공시 • Apr 05Vimian Group AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.632566 billion.Vimian Group AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.632566 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 65,302,624 Price\Range: SEK 25 Transaction Features: Regulation S; Rights Offering공시 • Dec 22Vimian Group AB (publ) Announces CEO ChangesVimian Group AB (publ) appoints Patrik Eriksson Chief Executive Officer, effective 1 January 2024. Patrik Eriksson joins Vimian from Envista, a global dental company listed on NYSE, where he currently serves on the Executive Team as President of Nobel Biocare. Patrik Eriksson (56) has vast international experience from 25 years as general manager in the global medtech and life science industries. Since 2020, he is President of the dental company Nobel Biocare, part of Envista. Prior to that, he worked seven years at the global life sciences group Danaher (NYSE:DHR) as President of two of its medtech companies, KavoKerr and Ormco. He has led international organizations with more than 6,500 employees and revenues of USD 1.5 billion. He is a Swedish citizen and holds a M.Sc. in Business and Administration from the Stockholm School of Economics. Patrik Eriksson succeeds Fredrik Ullman whose departure at year-end was announced on 29 June 2023.공시 • Sep 26Fidelio Capital acquired a 12% stake in Vimian Group AB (publ) for approximately SEK 240 million.Fidelio Capital acquired a 12% stake in Vimian Group AB (publ) for approximately SEK 240 million on September 21, 2023. Fidelio Capital completed the acquisition of a 12% stake in Vimian Group AB (publ) on September 21, 2023.공시 • Sep 13+ 5 more updatesVimian Group AB (publ) to Report Q3, 2024 Results on Oct 24, 2024Vimian Group AB (publ) announced that they will report Q3, 2024 results on Oct 24, 2024공시 • Jun 30Vimian Group AB (publ) Announces Fredrik Ullman Step Down as CEOVimian Group AB (publ) announced that CEO Fredrik Ullman, following consultation with the Board, steps down as CEO. Fredrik Ullman has been the CEO of Vimian since its inception in 2020 and the CEO of its subsidiary Indical Bioscience since 2018. The recruitment process for a new CEO will be initiated immediately with Fredrik Ullman remaining as CEO in the interim and at the latest until year-end. The recruitment process for a new CEO will be initiated immediately and Fredrik Ullman will remain as CEO in the interim.공시 • Jun 03Vimian Group AB (Publ) Elects Robert Belkic as New Board MemberVimian Group AB (publ) at the Annual General Meeting 2 June 2023, announced Robert Belkic was newly elected, as Board members for the time until the end of the next Annual General Meeting.공시 • Nov 17+ 2 more updatesVimian Group AB (publ) to Report Q2, 2023 Results on Aug 17, 2023Vimian Group AB (publ) announced that they will report Q2, 2023 results on Aug 17, 2023공시 • Oct 25Vimian Group AB (publ), Annual General Meeting, Jun 01, 2023Vimian Group AB (publ), Annual General Meeting, Jun 01, 2023.이익 및 매출 성장 예측OTCPK:VIMG.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20285538083117312/31/20275067167100412/31/2026463576089412/31/20254253191106N/A9/30/2025421326075N/A6/30/2025404236680N/A3/31/2025391195164N/A12/31/2024375194458N/A9/30/202435203651N/A6/30/2024345103146N/A3/31/20243358-34-18N/A12/31/202333210-43-29N/A9/30/2023325-5-36-25N/A6/30/2023316-14-53-42N/A3/31/2023301-7515N/A12/31/2022281-71525N/A9/30/202225516-63N/A6/30/202222517314N/A3/31/20221984518N/A12/31/20211737516N/A9/30/202115358919N/A6/30/202113258717N/A3/31/202110460614N/A12/31/20207153-15N/A12/31/201925-102N/A12/31/20188-1N/A-2N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: VIMG.F 의 연간 예상 수익 증가율(28%)이 saving rate(3.4%)보다 높습니다.수익 vs 시장: VIMG.F 의 연간 수익(28%)이 US 시장(16.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: VIMG.F 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: VIMG.F 의 수익(연간 8.7%)이 US 시장(연간 11.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: VIMG.F 의 수익(연간 8.7%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: VIMG.F의 자본 수익률은 3년 후 9.2%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/03/16 02:04종가2025/12/17 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Vimian Group AB (publ)는 10명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullABG Sundal CollierJonathon UnwinBarclaysKristofer Liljeberg-SvenssonCarnegie Investment Bank AB7명의 분석가 더 보기
공시 • Apr 29Vimian Group AB (publ) to Report Fiscal Year 2026 Results on Feb 11, 2027Vimian Group AB (publ) announced that they will report fiscal year 2026 results on Feb 11, 2027
공시 • Dec 24Vimian Group AB (publ) (OM:VIMIAN) entered into an agreement to acquire I-Vet S.R.L. from the Franzini family.Vimian Group AB (publ) (OM:VIMIAN) entered into an agreement to acquire I-Vet S.R.L. from the Franzini family on December 23, 2025. The acquisition is financed with available funds. Following the acquisition, I-Vet will be integrated into Vimian’s Diagnostics segment, and CEO Daniele Franzini will continue to lead I-Vet as part of Vimian. For the period ending December 31, 2024, I-Vet S.R.L. reported total revenue of €5.6 million and has 75 team members. The acquisition is expected to be completed on or around March 2, 2026. The acquisition is expected to have marginal impact on earnings per share in the 2026 financial year.
공시 • Nov 24+ 1 more updateVimian Group AB (publ) Announces CEO ChangesVimian Group AB (publ) appointed Alireza Tajbakhsh as Chief Executive Officer, effective 24 November 2025. Alireza Tajbakhsh joined Vimian in 2021 and is currently Head of the Veterinary Services segment and interim Head of the MedTech segment in Vimian. Alireza Tajbakhsh (42) brings extensive international leadership experience from fast-growing entrepreneurial companies in the media and life science sectors. Since joining Vimian in 2021, he has successfully led the Veterinary Services segment and served as a member of the group management team. Since July 2025, he has also held the interim position as Head of Vimian’s MedTech segment, delivering strong early progress and results. Prior to joining Vimian, Alireza held senior management positions at Omnicom Media Group and Modern Times Group (MTG). Alireza holds an M.Sc. in Business and Administration from the Stockholm School of Economics. The board thank Carl-Johan Zetterberg Boudrie for capably serving as interim CEO in addition to his role as CFO over the past months. Carl-Johan Zetterberg will continue as a strong partner to Ali in his position as CFO. Alireza Tajbakhsh will, in addition to the role as Group CEO, continue to hold the interim operational responsibility for Vimian's MedTech segment, while the recruitment for a permanent Head of MedTech is ongoing.
공시 • Oct 20Vimian Group AB (publ) to Report Fiscal Year 2025 Final Results on Mar 19, 2026Vimian Group AB (publ) announced that they will report fiscal year 2025 final results on Mar 19, 2026
공시 • Sep 23Vimian Group AB (publ), Annual General Meeting, Apr 29, 2026Vimian Group AB (publ), Annual General Meeting, Apr 29, 2026.
공시 • Sep 16+ 2 more updatesVimian Group AB (publ) to Report Q1, 2026 Results on Apr 29, 2026Vimian Group AB (publ) announced that they will report Q1, 2026 results on Apr 29, 2026
공시 • Jul 18+ 1 more updateVimian Group AB Announces Executive Management Changes, Effective 17 July 2025Vimian Group AB announced that effective today, Alireza Tajbakhsh will, in addition to his current role as Head of Vimian’s Veterinary Services segment, assume interim operational responsibility for Vimian’s MedTech segment. He succeeds Guy Spörri, who has decided to leave the company at year-end. Furthermore, Bart Bremer, Chief People Officer, is appointed as a member of Vimian’s executive management team.
공시 • Jun 13Vimian Group AB (publ) (OM:VIMIAN) signed an agreement to acquire AllAccem Inc.Vimian Group AB (publ) (OM:VIMIAN) signed an agreement to acquire AllAccem Inc. on June 13, 2025. AllAccem Inc. had revenues of around $9 million for the twelve months ending April 2025, and an EBITDA margin significantly above the Vimian Group average. AllAccem will become part of Vimian’s MedTech segment and Jeffery Whiteford, founder and CEO of AllAccem Inc., will continue to lead the integrated business. The acquisition is expected to have marginal impact on earnings per share in the current financial year. The acquisition of AllAccem Inc. is expected to be completed on or around 13 June and is financed with available funds.
공시 • Apr 30Vimian Group AB (publ) Elects Pia Marions as Board MemberVimian Group AB (publ) at its Annual General Meeting held on 29 April 2025, Pia Marions was newly elected, as Board members for the time until the end of the next Annual General Meeting.
공시 • Mar 14Vimian Group AB (publ) to Report Q4, 2025 Results on Feb 12, 2026Vimian Group AB (publ) announced that they will report Q4, 2025 results on Feb 12, 2026
공시 • Dec 04+ 3 more updatesVimian Group AB (publ) to Report Q2, 2025 Results on Jul 18, 2025Vimian Group AB (publ) announced that they will report Q2, 2025 results on Jul 18, 2025
공시 • Oct 12Vimian Group AB (publ), Annual General Meeting, Apr 29, 2025Vimian Group AB (publ), Annual General Meeting, Apr 29, 2025.
공시 • May 23Vimian Group AB (publ) Elects Magnus Welander to Board as Chairman of the BoardVimian Group AB (publ) at its Annual General Meeting held on 22 May 2024 announced that Magnus Welander was newly elected, as Board members for the time until the end of the next Annual General Meeting. Magnus Welander was elected as chairman of the Board.
공시 • Apr 05Vimian Group AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.632566 billion.Vimian Group AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.632566 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 65,302,624 Price\Range: SEK 25 Transaction Features: Regulation S; Rights Offering
공시 • Dec 22Vimian Group AB (publ) Announces CEO ChangesVimian Group AB (publ) appoints Patrik Eriksson Chief Executive Officer, effective 1 January 2024. Patrik Eriksson joins Vimian from Envista, a global dental company listed on NYSE, where he currently serves on the Executive Team as President of Nobel Biocare. Patrik Eriksson (56) has vast international experience from 25 years as general manager in the global medtech and life science industries. Since 2020, he is President of the dental company Nobel Biocare, part of Envista. Prior to that, he worked seven years at the global life sciences group Danaher (NYSE:DHR) as President of two of its medtech companies, KavoKerr and Ormco. He has led international organizations with more than 6,500 employees and revenues of USD 1.5 billion. He is a Swedish citizen and holds a M.Sc. in Business and Administration from the Stockholm School of Economics. Patrik Eriksson succeeds Fredrik Ullman whose departure at year-end was announced on 29 June 2023.
공시 • Sep 26Fidelio Capital acquired a 12% stake in Vimian Group AB (publ) for approximately SEK 240 million.Fidelio Capital acquired a 12% stake in Vimian Group AB (publ) for approximately SEK 240 million on September 21, 2023. Fidelio Capital completed the acquisition of a 12% stake in Vimian Group AB (publ) on September 21, 2023.
공시 • Sep 13+ 5 more updatesVimian Group AB (publ) to Report Q3, 2024 Results on Oct 24, 2024Vimian Group AB (publ) announced that they will report Q3, 2024 results on Oct 24, 2024
공시 • Jun 30Vimian Group AB (publ) Announces Fredrik Ullman Step Down as CEOVimian Group AB (publ) announced that CEO Fredrik Ullman, following consultation with the Board, steps down as CEO. Fredrik Ullman has been the CEO of Vimian since its inception in 2020 and the CEO of its subsidiary Indical Bioscience since 2018. The recruitment process for a new CEO will be initiated immediately with Fredrik Ullman remaining as CEO in the interim and at the latest until year-end. The recruitment process for a new CEO will be initiated immediately and Fredrik Ullman will remain as CEO in the interim.
공시 • Jun 03Vimian Group AB (Publ) Elects Robert Belkic as New Board MemberVimian Group AB (publ) at the Annual General Meeting 2 June 2023, announced Robert Belkic was newly elected, as Board members for the time until the end of the next Annual General Meeting.
공시 • Nov 17+ 2 more updatesVimian Group AB (publ) to Report Q2, 2023 Results on Aug 17, 2023Vimian Group AB (publ) announced that they will report Q2, 2023 results on Aug 17, 2023
공시 • Oct 25Vimian Group AB (publ), Annual General Meeting, Jun 01, 2023Vimian Group AB (publ), Annual General Meeting, Jun 01, 2023.